S&P 500   3,453.49 (+0.52%)
DOW   28,363.66 (+0.54%)
QQQ   284.21 (+0.01%)
AAPL   115.88 (-0.85%)
MSFT   214.62 (-0.08%)
FB   278.42 (-0.11%)
GOOGL   1,607.28 (+1.34%)
AMZN   3,180.00 (-0.16%)
TSLA   426.84 (+0.99%)
NVDA   532.68 (-1.54%)
BABA   306.36 (-0.52%)
CGC   20.30 (+4.16%)
GE   7.72 (+5.46%)
MU   53.88 (+1.07%)
AMD   79.93 (+0.92%)
T   28.26 (+5.76%)
F   8.21 (+4.59%)
ACB   4.85 (+0.00%)
GILD   62.75 (+4.22%)
NFLX   485.23 (-0.78%)
BA   168.97 (+3.12%)
NIO   27.41 (-1.62%)
BAC   24.89 (+3.49%)
S&P 500   3,453.49 (+0.52%)
DOW   28,363.66 (+0.54%)
QQQ   284.21 (+0.01%)
AAPL   115.88 (-0.85%)
MSFT   214.62 (-0.08%)
FB   278.42 (-0.11%)
GOOGL   1,607.28 (+1.34%)
AMZN   3,180.00 (-0.16%)
TSLA   426.84 (+0.99%)
NVDA   532.68 (-1.54%)
BABA   306.36 (-0.52%)
CGC   20.30 (+4.16%)
GE   7.72 (+5.46%)
MU   53.88 (+1.07%)
AMD   79.93 (+0.92%)
T   28.26 (+5.76%)
F   8.21 (+4.59%)
ACB   4.85 (+0.00%)
GILD   62.75 (+4.22%)
NFLX   485.23 (-0.78%)
BA   168.97 (+3.12%)
NIO   27.41 (-1.62%)
BAC   24.89 (+3.49%)
S&P 500   3,453.49 (+0.52%)
DOW   28,363.66 (+0.54%)
QQQ   284.21 (+0.01%)
AAPL   115.88 (-0.85%)
MSFT   214.62 (-0.08%)
FB   278.42 (-0.11%)
GOOGL   1,607.28 (+1.34%)
AMZN   3,180.00 (-0.16%)
TSLA   426.84 (+0.99%)
NVDA   532.68 (-1.54%)
BABA   306.36 (-0.52%)
CGC   20.30 (+4.16%)
GE   7.72 (+5.46%)
MU   53.88 (+1.07%)
AMD   79.93 (+0.92%)
T   28.26 (+5.76%)
F   8.21 (+4.59%)
ACB   4.85 (+0.00%)
GILD   62.75 (+4.22%)
NFLX   485.23 (-0.78%)
BA   168.97 (+3.12%)
NIO   27.41 (-1.62%)
BAC   24.89 (+3.49%)
S&P 500   3,453.49 (+0.52%)
DOW   28,363.66 (+0.54%)
QQQ   284.21 (+0.01%)
AAPL   115.88 (-0.85%)
MSFT   214.62 (-0.08%)
FB   278.42 (-0.11%)
GOOGL   1,607.28 (+1.34%)
AMZN   3,180.00 (-0.16%)
TSLA   426.84 (+0.99%)
NVDA   532.68 (-1.54%)
BABA   306.36 (-0.52%)
CGC   20.30 (+4.16%)
GE   7.72 (+5.46%)
MU   53.88 (+1.07%)
AMD   79.93 (+0.92%)
T   28.26 (+5.76%)
F   8.21 (+4.59%)
ACB   4.85 (+0.00%)
GILD   62.75 (+4.22%)
NFLX   485.23 (-0.78%)
BA   168.97 (+3.12%)
NIO   27.41 (-1.62%)
BAC   24.89 (+3.49%)
Log in
NYSEAMERICAN:ISR

Isoray Stock Forecast, Price & News

$0.40
0.00 (-0.90 %)
(As of 10/22/2020 03:59 PM ET)
Add
Compare
Today's Range
$0.38
Now: $0.40
$0.41
50-Day Range N/A
52-Week Range
$0.29
Now: $0.40
$1.06
Volume180,147 shs
Average Volume516,945 shs
Market Capitalization$27.31 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma. It sells its products to facilities or physician practices that utilize multiple surgical facilities at which primarily prostate brachytherapy procedures are performed. Isoray, Inc. was founded in 1998 and is headquartered in Richland, Washington.
Read More
Isoray logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.25 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Medical Instruments & Supplies
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:ISR
Previous SymbolNYSEMKT:ISR
CUSIPN/A
Phone+1-509-3751202
Employees53

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$27.31 million
Next Earnings Date11/10/2020 (Estimated)
OptionableNot Optionable
$0.40
0.00 (-0.90 %)
(As of 10/22/2020 03:59 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ISR News and Ratings via Email

Sign-up to receive the latest news and ratings for ISR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Isoray (NYSEAMERICAN:ISR) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Isoray?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Isoray in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Isoray
.

When is Isoray's next earnings date?

Isoray is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Isoray
.

How were Isoray's earnings last quarter?

Isoray, Inc. (NYSEAMERICAN:ISR) released its earnings results on Thursday, September, 17th. The healthcare company reported ($0.02) earnings per share for the quarter, missing the consensus estimate of ($0.01) by $0.01. The healthcare company earned $2.28 million during the quarter, compared to analyst estimates of $2.77 million.
View Isoray's earnings history
.

What guidance has Isoray issued on next quarter's earnings?

Isoray issued an update on its first quarter 2021 After-Hours earnings guidance on Thursday, September, 17th. The company provided EPS guidance of for the period. The company issued revenue guidance of $2.3-2.5 million, compared to the consensus revenue estimate of $3.1 million.

What price target have analysts set for ISR?

3 analysts have issued 1 year price objectives for Isoray's shares. Their forecasts range from $1.25 to $1.75. On average, they anticipate Isoray's share price to reach $1.50 in the next twelve months. This suggests a possible upside of 278.4% from the stock's current price.
View analysts' price targets for Isoray
.

Are investors shorting Isoray?

Isoray saw a decrease in short interest during the month of September. As of September 30th, there was short interest totaling 1,310,000 shares, a decrease of 12.7% from the September 15th total of 1,500,000 shares. Based on an average daily trading volume, of 351,500 shares, the days-to-cover ratio is presently 3.7 days.
View Isoray's Short Interest
.

Who are some of Isoray's key competitors?

What other stocks do shareholders of Isoray own?

Who are Isoray's key executives?

Isoray's management team includes the following people:
  • Ms. Lori A. Holmes-Woods, CEO & Director (Age 58, Pay $392.94k)
  • Mr. Michael L. Krachon, Exec. VP of Sales & Marketing (Age 49, Pay $285.92k)
  • Mr. William A. Cavanagh III, Chief R&D Officer (Age 54, Pay $258.8k)
  • Mr. Jonathan R. Hunt, CFO & Co-Principal Financial Officer (Age 53)
  • Ms. Jennifer Streeter, COO & VP of HR (Age 50)

What is Isoray's stock symbol?

Isoray trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ISR."

Who are Isoray's major shareholders?

Isoray's stock is owned by many different retail and institutional investors. Top institutional investors include Avantax Advisory Services Inc. (0.07%). Company insiders that own Isoray stock include Alan Hoffmann, Lori A Woods, Mark John Austin, Michael Krachon, Philip J Vitale and William Cavanagh.
View institutional ownership trends for Isoray
.

Which institutional investors are buying Isoray stock?

ISR stock was purchased by a variety of institutional investors in the last quarter, including Avantax Advisory Services Inc.. Company insiders that have bought Isoray stock in the last two years include Alan Hoffmann, Lori A Woods, Mark John Austin, Michael Krachon, Philip J Vitale, and William Cavanagh.
View insider buying and selling activity for Isoray
.

How do I buy shares of Isoray?

Shares of ISR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Isoray's stock price today?

One share of ISR stock can currently be purchased for approximately $0.40.

How big of a company is Isoray?

Isoray has a market capitalization of $27.31 million. Isoray employs 53 workers across the globe.

What is Isoray's official website?

The official website for Isoray is isoray.com.

How can I contact Isoray?

Isoray's mailing address is 350 Hills St Ste 106, RICHLAND, WA 99354-5511, United States. The healthcare company can be reached via phone at +1-509-3751202.

This page was last updated on 10/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.